From: Angiotensin receptor blockers in heart failure after the ELITE II trial
Power primary endpoint | Expected | |||||
---|---|---|---|---|---|---|
Study | Drugs | Type of patients | n | reduction (%) | Endpoints | to be concluded |
Val-HeFT | Valsartan vs placebo | Symptomatic HF, | 5009 | 20 | Total mortality | 2000 |
(open ACEi) | LVEF ≤ 40% | Morbidity | 906 deaths | |||
CHARM | Candesartan vs placebo | Symptomatic HF + | 16-20 | CV mortality/ | 2002 | |
LVEF≤ 40, on ACEi | 2550 | HF hospitalization | ||||
LVEF≤ 40, ACEi intolerant | 2000 | (total mortality in | ||||
LVEF> 40, no ACEi | 2970 | the combined arms) |